Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Publisher



Khani L1 ; Jazayeri MH1, 2 ; Nedaeinia R3 ; Bozorgmehr M4 ; Nabavi SM5 ; Ferns GA6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Iran University of Medical Science, Shahid Hemmat Highway, P.O Box 14665-354, Tehran, 14496-14535, Iran
  2. 2. Immunology Research Center, Iran University of Medical Science, Shahid Hemmat Highway, P.O Box 14665-354, Tehran, 14496-14535, Iran
  3. 3. Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Oncopathology Research Center, Iran University of Medical Science, Tehran, Iran
  5. 5. Department of Regenerative Biomedicine, Cell Science Research Center, Neuroscience and Cognition Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  6. 6. Division of Medical Education, Brighton and Sussex Medical School, Falmer, Sussex, Brighton, BN1 9PH, United Kingdom

Source: Allergy, Asthma and Clinical Immunology Published:2022


Abstract

Background: Multiple sclerosis (MS) and neuromyelitis optica syndrome disease (NMOSD) are inflammatory diseases of the central nervous system. The pathogenesis and treatments for these two conditions are very different. Natural killer (NK) and natural killer T (NKT) cells are immune cells with an important role in shaping the immune response. B cells are involved in antigen presentation as well as antibody and cytokine production. There is conflicting evidence of the roles of NK, NKT, and B cells in the two conditions. We aimed to compare the frequency of CD3−CD16+CD56+NK, CD3+ CD56+ NKT, and CD5+CD19+ B cells in the peripheral blood and serum Interleukin-10 (IL-10) in patients with MS and NMOSD. Methods: CD19+CD5+ B, CD3− CD16+CD56+ NK, and CD3+CD56+ NKT cells were quantitated by flow cytometry in 15 individuals with Interferon-Beta (IFN-β) treated relapsing–remitting MS (RRMS), 15 untreated RRMS, and 15 NMOSD patients as well as 30 healthy controls (HC). Serum IL-10 was measured using an enzyme-linked immunosorbent assay (ELISA). Results: The percentage of CD3−CD56+CD16+ NK cells in the peripheral blood of IFN-treated MS (1.81 ± 0.87) was significantly lower than for untreated RRMS (4.74 ± 1.80), NMOSD (4.64 ± 1.26) and HC (5.83 ± 2.19) (p < 0.0001). There were also differences for the percentage of CD3−CD16+ and CD3−CD56+ cells (p < 0.001 and p < 0.0007; respectively). IFN-treated RRMS (2.89 ± 1.51) had the lowest proportion of CD3+CD56+ among the study groups (p < 0.002). Untreated RRMS (5.56 ± 3.04) and NMOSD (5.47 ± 1.24) had higher levels of CD3+CD56+ than the HC (3.16 ± 1.98). The mean percentage of CD19+CD5+ B cells in the peripheral blood of untreated RRMS patients (1.32 ± 0.67) was higher compared to the patients with NMOSD (0.30 ± 0.20), HC (0.5 ± 0.22) and IFN-treated RRMS (0.81 ± 0.17) (p < 0.0001). Serum interleukin-10 was significantly higher in the IFN-treated RRMS (8.06 ± 5.39) and in HC (8.38 ± 2.84) compared to untreated RRMS (5.07 ± 1.44) and the patients with NMOSD (5.33 ± 2.56) (p < 0.003). Conclusions: The lower proportion of CD3−CD56+ CD16+ NK and CD3+CD56+ cells in peripheral blood of IFN-treated RRMS compared to other groups suggests the importance of immunomodulation in patients with RRMS disorder. Based on the differences in CD19+CD5+ B cells and serum IL-10 between patients and HC, supplementary assessments could be of value in clarifying their roles in autoimmunity. © 2022, The Author(s).
Related Docs
View other Related Docs
1. The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies, Health Science Reports (2022)
2. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
3. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
4. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
5. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
6. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
7. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
8. Short-Term Effect of High-Dose Vitamin D on the Level of Interleukin 10 in Patients With Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, NeuroImmunoModulation (2015)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (43)
Masoud Etemadifar (43)
Other Related Docs
9. Effect of High Dose Vitamin D Intake on Interleukin-17 Levels in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Neuroimmunology (2015)
10. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
11. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
12. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
13. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
14. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
15. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
16. Neurological Efficacy and Safety of Mesenchymal Stem Cells (Mscs) Therapy in People With Multiple Sclerosis (Pwms): An Updated Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
17. Interleukin-10 and Brain-Derived Neurotrophic Factor Responses to the Mat Pilates Training in Women With Multiple Sclerosis, Scientia Medica (2018)
18. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
19. Immune-Dysregulation Harnessing in Myeloid Neoplasms, Cancer Medicine (2024)
20. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
21. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
22. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
23. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
24. Evaluation of Edaravone Effects on the Differentiation of Human Adipose Derived Stem Cells Into Oligodendrocyte Cells in Multiple Sclerosis Disease in Rats, Life Sciences (2021)
25. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
26. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)
27. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
28. Expression of Chemokine Receptors on Th1/Th2 Cd4+ Lymphocytes in Patients With Multiple Sclerosis, Iranian Journal of Immunology (2011)
29. Long-Term Tolerability, Safety and Efficacy of Rituximab in Neuromyelitis Optica Spectrum Disorder: A Prospective Study, Journal of Neurology (2019)
30. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
31. Research Paper: Assessment the Possible Association Between Neuromyelitis Optica and Cytomegalovirus As a Provocative Factor, Caspian Journal of Neurological Sciences (2019)
32. Immune System Changes During Covid-19 Recovery Play Key Role in Determining Disease Severity, International Journal of Immunopathology and Pharmacology (2020)
33. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
34. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
35. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
36. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)
37. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
38. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
39. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
40. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
41. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
42. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
43. Myasthenia Gravis During the Course of Neuromyelitis Optica, Case Reports in Neurology (2011)
44. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
45. Efficacy and Safety of Rituximab in Neuromyelitis Optica: Review of Evidence, Journal of Research in Medical Sciences (2017)
46. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
47. Revisiting the Antiviral Theory to Explain Interferon-Beta's Effectiveness for Relapsing Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
48. Is Fertility Affected in Women of Childbearing Age With Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?, Journal of Molecular Neuroscience (2020)
49. Research Paper: The Association Between Salt and Potassium Intake With Multiple Sclerosis, Caspian Journal of Neurological Sciences (2019)
50. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)